These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36467832)

  • 1. Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis.
    Manwani D; Burnett AL; Paulose J; Yen GP; Burton T; Anderson A; Wang S; Lee S; Saraf SL
    EJHaem; 2022 Nov; 3(4):1135-1144. PubMed ID: 36467832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
    Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
    BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
    Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
    Kanter J; Bhor M; Li X; Li FY; Paulose J
    J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
    Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related prescription medication utilization for the -management of sickle cell disease among Texas Medicaid patients.
    Shukla N; Barner JC; Lawson KA; Rascati KL
    J Opioid Manag; 2021; 17(4):301-310. PubMed ID: 34533824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review.
    Lee S; Vania DK; Bhor M; Revicki D; Abogunrin S; Sarri G
    Int J Gen Med; 2020; 13():361-377. PubMed ID: 32753936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA; Barner JC
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [No Abstract]   [Full Text] [Related]  

  • 13. Opioid Prescribing and Outcomes in Patients With Sickle Cell Disease Post-2016 CDC Guideline.
    Kang HA; Wang B; Barner JC; Ataga KI; Mignacca RC; Chang A; Zhang Y
    JAMA Intern Med; 2024 May; 184(5):510-518. PubMed ID: 38466269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
    Shah N; Bhor M; Xie L; Paulose J; Yuce H
    J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
    Gallagher ME; Chawla A; Brady BL; Badawy SM
    J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE; Nevitt SJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.